Company / FCF Margin
Inhibrx Biosciences, Inc. FCF Margin History
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-9986.5%
FY2025
5-year range
-10994.6% / -9986.5%
FY2024-FY2025
Trend
+9.2%
vs FY2024
Sector context
#133 of 134
Health Care
What the data says
Among 134 Health Care companies, Inhibrx Biosciences, Inc. is in the bottom 1% for fcf margin.
Based on SEC 10-K filings.
-9986.5% in FY2025.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 134This company -9986.5% Sector average -637.8%
▼
-1465.8% below sector average
Key checks
Key Insights
- In FY2025, fcf margin increased 9.2% year-over-year.
- Currently 9348.8pp below the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -9986.5% | +9.2% |
| FY2024 | -10994.6% | - |
| FY2023 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026